Methenamine Hippurate is globally recognised and utilised in over 30 countries including the US, Europe and Chile
Cipla has launched Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA.
Achin Gupta, Global Chief Operating Officer, Cipla, said: “The launch of HUENA reflects our strong commitment to antimicrobial stewardship and addressing the growing challenge of AMR. We believe this innovation will notably improve patient outcomes, while reducing reliance on antibiotics, further contributing to a healthier future for all.”
Dr Jaideep Gogtay, Global Chief Medical Officer, Cipla, said, “At Cipla, we recognise the urgent need for innovative solutions to combat the growing burden of AMR. This groundbreaking launch provides patients with a non-antibiotic drug that will help prevent urinary tract infections without contributing to antimicrobial resistance.”
